Artificial Intelligence in Drug Discovery and Development Nptel Week 1 Answers

Are you looking for AI in Drug Discovery and Development Week 1 Answers ? All weeks solutions of this swayam course assignment are available here.


AI in Drug Discovery and Development Week 1 Answers
Artificial Intelligence in Drug Discovery and Development Week 1 Answers

AI in Drug Discovery and Development Week 1 Answers (July-Dec 2025)

Course link: Click here to visit course on Nptel Website


Question 1. Which of the following is not typically part of the Drug Discovery Phase?

a) Target identification and validation
b) Compound screening and lead discovery
c) Preclinical development
d) Regulatory submissions

View Answer


Question 2. What is the average success rate and duration of the Drug Development Phase?

a) 2–5% success rate; 3–5 years
b) 5–20% success rate; 4–6 years
c) 20–50% success rate; 2–4 years
d) 10–30% success rate; 6–8 years

View Answer


Question 3. Which of the following is not a role of regulatory agencies in drug development?

a) Reviewing and approving new drug applications
b) Conducting clinical trials
c) Ensuring drug safety and efficacy
d) Post-market surveillance for long-term safety

View Answer

These are AI in Drug Discovery and Development Week 1 Answers


Question 4. What is the purpose of using organ-on-a-chip technology in drug development?

a) Enhancing artificial intelligence models
b) Predicting molecular interactions
c) Mimicking human physiology for better preclinical testing
d) Performing high-throughput screening

View Answer


Question 5. Which of the following is not typically considered a stakeholder in the drug discovery process?

a) Pharmaceutical companies
b) Academic institutions
c) Real estate developers
d) Government agencies

View Answer


Question 6. Which of the following diseases is commonly targeted under the Orphan Drug Act?

a) Osteoporosis
b) Pompe Disease
c) Arthritis
d) Hypertension

View Answer

These are AI in Drug Discovery and Development Week 1 Answers


Question 7. Which of the following is not a desirable characteristic when converting a hit molecule to a lead compound?

a) Higher potency
b) Poor pharmacokinetics
c) Chemical modifiability
d) Higher selectivity

View Answer


Question 8. In which clinical trial phase is the optimal dose and short-term side effects of a drug assessed?

a) Phase 0
b) Phase I
c) Phase II
d) Phase III

View Answer


Question 9. Which of the following studies is used to assess drug metabolism in preclinical testing?

a) Plasma protein binding assay
b) Blood-brain barrier permeability
c) Caco-2 permeability assay
d) CYP450 inhibition assay

View Answer

These are AI in Drug Discovery and Development Week 1 Answers


Question 10. Which of the following statements is TRUE regarding IC50?

a) A higher IC50 indicates a more potent inhibitor.
b) IC50 measures the concentration needed to bind 100% of the enzyme.
c) A lower IC50 value corresponds to higher inhibitor potency.
d) IC50 is unrelated to enzyme inhibition.

View Answer


Question 11. What is the primary purpose of Caco-2 permeability studies?

a) To determine plasma protein binding of a drug
b) To assess drug metabolism using liver enzymes
c) To evaluate passive membrane permeability
d) To predict oral absorption potential of a drug

View Answer


Question 12. Why can implicit solvent models be problematic in MD simulations?

a) They require high computational cost
b) They oversimplify solvation effects
c) They enhance hydrogen bonding
d) They model explicit ion effects better

View Answer


Question 13. Which type of molecule binds to a receptor and reduces its activity below its normal level?

a) Agonist
b) Antagonist
c) Partial agonist
d) Inverse agonist

View Answer

These are AI in Drug Discovery and Development Week 1 Answers


Question 14. Which in vitro ADME method uses synthetic lipid membranes to measure passive drug permeability?

a) Microsomal stability assay
b) Caco-2 permeability studies
c) Plasma protein binding experiments
d) Parallel artificial membrane permeability assay (PAMPA)

View Answer


Question 15. Which of the following is a major challenge in precision medicine related to data management?

a) High mutation rates
b) Data integration from genomic, clinical, and environmental sources
c) Inconsistent dosing guidelines
d) Limited availability of vaccines

View Answer


These are AI in Drug Discovery and Development Week 1 Answers

Click here for all nptel assignment answers